COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients.

Publication date: Dec 01, 2023

The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who had received anti-CD20 therapy within the 3 years prior to infection. We compared outcomes between those treated with and those not treated with high titer SARS-CoV2 convalescent plasma. We identified 144 adults treated at Mayo clinic sites who had received anti-CD20 therapies within a median of 5. 9 months prior to the COVID-19 index date. About one-third (34. 7%) were hospitalized within 14 days and nearly half (47. 9%) within 90 days. COVID-19 directed therapy included anti-spike monoclonal antibodies (n = 30, 20. 8%), and, among those hospitalized within 14 days (n = 50), remdesivir (n = 45, 90. 0%), glucocorticoids (n = 36, 72. 0%) and convalescent plasma (n = 24, 48. 0%). The duration from receipt of last dose of anti-CD20 therapy did not correlate with outcomes. The overall 90-day mortality rate was 14. 7%. Administration of convalescent plasma within 14 days of the COVID-19 diagnosis was not significantly associated with any study outcome. Further study of COVID-19 in CD20-depleted individuals is needed focusing on the early administration of new and potentially combination antiviral agents, associated or not with vaccine-boosted convalescent plasma.

Open Access PDF

Concepts Keywords
14days Anti
Controversial Cd20
Coronavirus Convalescent
Therapy Coronavirus
Covid
High
Immunosuppressed
Individuals
Outcome
Plasma
Received
Sars
Therapy
Titer
Treated

Semantics

Type Source Name
disease MESH COVID-19
disease VO titer
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH infection
disease VO dose
disease VO vaccine
drug DRUGBANK Coenzyme M
disease MESH Emergency
disease VO organization
disease VO vaccination
disease MESH Infectious Diseases
disease VO USA
pathway REACTOME Infectious disease
disease IDO infectious disease
drug DRUGBANK Etoperidone
disease VO population
disease VO primary vaccination
disease MESH vasculitis
drug DRUGBANK Rituximab
drug DRUGBANK Obinutuzumab
drug DRUGBANK Ocrelizumab
disease MESH viral shedding
disease IDO cell
disease MESH Hematologic malignancy
disease MESH seroconversion
disease MESH clinical course
disease VO time
drug DRUGBANK Methionine
pathway KEGG Viral replication
drug DRUGBANK Trestolone
disease VO frequency
disease MESH morbidity
disease MESH Malignancy
disease MESH Diabetes mellitus
drug DRUGBANK Oxygen
disease MESH Death
disease VO vaccinated
disease MESH lymphopenia
disease MESH inflammation
disease VO unvaccinated
drug DRUGBANK Indoleacetic acid
disease MESH immunocompromised patients
disease IDO immunosuppression
disease MESH chronic obstructive lung disease
disease VO effective
disease VO effectiveness
disease MESH uncertainty
drug DRUGBANK Dexamethasone
drug DRUGBANK Hydrocortisone
disease VO organ
disease MESH critically ill
drug DRUGBANK Baricitinib
disease MESH chronic lymphocytic leukemia
disease IDO blood
disease MESH musculoskeletal diseases
disease MESH severe acute respiratory syndrome
disease IDO replication
disease MESH leukemia
disease VO viable
disease IDO immune response
disease MESH systemic vasculitis
disease IDO immunodeficiency
disease MESH pneumonia
drug DRUGBANK Elm
disease MESH Respiratory failure
disease MESH sarcoidosis
disease MESH multiple sclerosis
disease MESH organizing pneumonia
disease MESH acute lymphoblastic leukemia
drug DRUGBANK Ritonavir

Original Article

(Visited 1 times, 1 visits today)